Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma | Gastroenterology | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Lee  WM Hepatitis B virus infection.  N Engl J Med 1997;337 (24) 1733- 1745PubMedGoogle ScholarCrossref
2.
El-Serag  HB Hepatocellular carcinoma: an epidemiologic view.  J Clin Gastroenterol 2002;35 (5) (suppl 2)S72- S78PubMedGoogle ScholarCrossref
3.
Yuen  MFSeto  WKChow  DH Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.  Antivir Ther 2007;12 (8) 1295- 1303PubMedGoogle Scholar
4.
Liaw  YFSung  JJChow  WCCirrhosis Asian Lamivudine Multicentre Study Group, Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med 2004;351 (15) 1521- 1531PubMedGoogle ScholarCrossref
5.
Matsumoto  ATanaka  ERokuhara  AInuyama Hepatitis Study Group, Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients.  Hepatol Res 2005;32 (3) 173- 184PubMedGoogle ScholarCrossref
6.
Di Marco  VMarzano  ALampertico  PItalian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy, Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology 2004;40 (4) 883- 891PubMedGoogle ScholarCrossref
7.
Kim  JHPark  JWKoh  DWLee  WJKim  CM Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus–related hepatocellular carcinoma.  Liver Int 2009;29 (2) 203- 207PubMedGoogle ScholarCrossref
8.
Kuzuya  TKatano  YKumada  T Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus–related hepatocellular carcinoma.  J Gastroenterol Hepatol 2007;22 (11) 1929- 1935PubMedGoogle ScholarCrossref
9.
Shuqun  CMengchao  WHan  C Antiviral therapy using lamivudine and thymosin α1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection.  Hepatogastroenterology 2006;53 (68) 249- 252PubMedGoogle Scholar
10.
Ercolani  GGrazi  GLRavaioli  M Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence.  Ann Surg 2003;237 (4) 536- 543PubMedGoogle Scholar
11.
Grazi  GLCescon  MRavaioli  M Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics: evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre.  Aliment Pharmacol Ther 2003;17(suppl 2)119- 129PubMedGoogle ScholarCrossref
12.
Poon  RTFan  STLo  CMLiu  CLNg  IOWong  J Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B–related cirrhosis.  J Clin Oncol 2000;18 (5) 1094- 1101PubMedGoogle Scholar
13.
Yasui  MHarada  ATorii  ANakao  ANonami  TTakagi  H Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma.  World J Surg 1995;19 (3) 439- 443PubMedGoogle ScholarCrossref
14.
Greene  FLBalch  CMPage  DLAmerican Joint Committee on Cancer Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002
15.
Poon  RTFan  ST Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome.  Liver Transpl 2004;10 (2) (suppl 1)S39- S45PubMedGoogle ScholarCrossref
16.
Fan  STLo  CMLiu  CL Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.  Ann Surg 1999;229 (3) 322- 330PubMedGoogle ScholarCrossref
17.
Liu  CLFan  STLo  CMTung-Ping Poon  RWong  J Anterior approach for major right hepatic resection for large hepatocellular carcinoma.  Ann Surg 2000;232 (1) 25- 31PubMedGoogle ScholarCrossref
18.
Kilic  ZMKuran  SAkdogan  M The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.  Adv Ther 2008;25 (3) 190- 200PubMedGoogle ScholarCrossref
19.
Nishida  TKobashi  HFujioka  S A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.  J Gastroenterol Hepatol 2008;23 (5) 794- 803PubMedGoogle ScholarCrossref
20.
Lai  CLShouval  DLok  ASBEHoLD AI463027 Study Group, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.  N Engl J Med 2006;354 (10) 1011- 1020PubMedGoogle ScholarCrossref
21.
Chang  TTGish  RGde Man  RBEHoLD AI463022 Study Group, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.  N Engl J Med 2006;354 (10) 1001- 1010PubMedGoogle ScholarCrossref
22.
Rizzetto  MTassopoulos  NCGoldin  RD Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.  J Hepatol 2005;42 (2) 173- 179PubMedGoogle ScholarCrossref
23.
Ko  SNakajima  YKanehiro  H Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy: result of multivariate analysis.  Ann Surg 1996;224 (5) 591- 595PubMedGoogle ScholarCrossref
24.
Shirabe  KTakenaka  KTaketomi  A Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma.  Cancer 1996;77 (6) 1050- 1055PubMedGoogle ScholarCrossref
25.
Tarao  KTakemiya  STamai  S Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus–associated cirrhosis and HCC.  Cancer 1997;79 (4) 688- 694PubMedGoogle ScholarCrossref
26.
Chen  CJYang  HISu  JREVEAL-HBV Study Group, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA 2006;295 (1) 65- 73PubMedGoogle ScholarCrossref
Original Article
June 2011June 20, 2011

Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma

Author Affiliations

Author Affiliations: Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region.

Arch Surg. 2011;146(6):675-681. doi:10.1001/archsurg.2011.125
Abstract

Objectives  To assess whether commencement of antiviral therapy after hepatectomy improves the prognosis of hepatocellular carcinoma (HCC) in preoperatively antiviral-naive patients with chronic hepatitis B virus (HBV) infection.

Design  Retrospective analysis of a prospectively collected database.

Setting  University teaching hospital.

Main Outcome Measures  Disease-free and overall survival rates.

Results  One hundred thirty-six patients received major hepatectomy for HBV-related HCC from September 1, 2003, through December 31, 2007. Among them, 42 patients received antiviral therapy (treatment group) after hepatectomy, whereas 94 did not (control group). Patient demographics, preoperative liver function, tumor characteristics, and liver function at the time of tumor recurrence were comparable between the 2 groups. Disease-free and overall survival rates were significantly prolonged in the treatment group. The 1-, 3-, and 5-year overall survival rates in the treatment group were 88.1%, 79.1%, and 71.2%, respectively; in the control group, 76.5%, 47.5%, and 43.5%, respectively (P = .005). The 1-, 3-, and 5-year disease-free survival rates in the treatment group were 66.5%, 51.4%, and 51.4%, respectively; in the control group, 48.9%, 33.8%, and 33.8%, respectively (P = .05). Subgroup analysis stratified against tumor stage and major vascular invasion showed that posthepatectomy antiviral treatment conferred a significant survival benefit in stages I and II tumors or HCCs without major venous invasion.

Conclusions  Antiviral therapy improves the prognosis of HBV-related HCC. It should be considered after hepatectomy for HBV-related HCC, especially in early-stage tumors.

×